Tactile Systems Technology (TCMD)
NASDAQ:TCMD
Want to see TCMD full AI Analyst Report?
TCMD Stock Chart & Stats
$25.73
$0.01(0.06%)
At close: 4:00 PM EST
$25.73
$0.01(0.06%)
Day’s Range― - ―
52-Week Range$9.34 - $37.77
Previous CloseN/A
Volume58.88K
Average Volume (3M)247.64K
Market Cap
$570.67M
Enterprise Value$526.87M
Total Cash (Recent Filing)$83.45M
Total Debt (Recent Filing)$15.96M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Aug 10, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.85
Shares Outstanding22,556,260
10 Day Avg. Volume229,559
30 Day Avg. Volume247,641
Financial Highlights & Ratios
PEG Ratio2.06
Price to Book (P/B)3.03
Price to Sales (P/S)2.01
P/FCF Ratio16.41
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue1.60
Enterprise Value/Gross Profit2.13
Enterprise Value/Ebitda13.81
Forecast
1Y Price Target
$39.50Price Target Upside53.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.14
Revenue Forecast (FY)$360.52M
Bulls Say, Bears Say
Bulls Say
Commercial Investments And Sales ProductivityInvestments in a larger field salesforce, improved customer relationship systems, and AI-driven patient engagement tools are scaling commercial reach and improving sales productivity, which should help sustain revenue growth.
Earnings And MarginsRevenue and gross margins significantly beat expectations, reflecting stronger-than-expected demand and margin expansion that may support higher profitability and investor confidence.
Strategic Acquisition And Product AdoptionAcquisition of LymphaTech could simplify limb volume measurement and increase diagnosis rates, encouraging broader adoption of the company’s pneumatic compression therapy and expanding the addressable market.
Bears Say
Medicare Prior AuthorizationA new Medicare prior authorization requirement could complicate patient access and slow therapy adoption within an important payer channel, creating a headwind for volume growth.
Reimbursement And Administrative BurdenPrior authorization logistics are likely to increase administrative workload and costs for providers and the company, which could pressure operating margins during the adjustment period.
Tactile Systems Technology News
TCMD FAQ
What was Tactile Systems Technology’s price range in the past 12 months?
Tactile Systems Technology lowest stock price was $9.34 and its highest was $37.77 in the past 12 months.
What is Tactile Systems Technology’s market cap?
Tactile Systems Technology’s market cap is $570.67M.
When is Tactile Systems Technology’s upcoming earnings report date?
Tactile Systems Technology’s upcoming earnings report date is Aug 10, 2026 which is in 93 days.
How were Tactile Systems Technology’s earnings last quarter?
Tactile Systems Technology released its earnings results on May 04, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.12 by $0.04.
Is Tactile Systems Technology overvalued?
According to Wall Street analysts Tactile Systems Technology’s price is currently Undervalued.
Does Tactile Systems Technology pay dividends?
Tactile Systems Technology does not currently pay dividends.
What is Tactile Systems Technology’s EPS estimate?
Tactile Systems Technology’s EPS estimate is 0.14.
How many shares outstanding does Tactile Systems Technology have?
Tactile Systems Technology has 22,556,260 shares outstanding.
What happened to Tactile Systems Technology’s price movement after its last earnings report?
Tactile Systems Technology reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.12. Following the earnings report the stock price went up 7.222%.
Which hedge fund is a major shareholder of Tactile Systems Technology?
Currently, no hedge funds are holding shares in TCMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tactile Systems Technology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.50 (53.52% Upside)
$39.50 (53.52% Upside)
Blogger Sentiment
Bullish
TCMD Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 565.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
93.02%
12-Months-Change
Fundamentals
Return on Equity
9.70%
Trailing 12-Months
Asset Growth
-2.90%
Trailing 12-Months
Company Description
Tactile Systems Technology
Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
TCMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed broad-based commercial strength (23% YoY revenue growth), margin expansion (gross margin +250 bps) and a turnaround to adjusted EBITDA profitability, supported by product clearances (next-gen AffloVest), AI deployment, and strategic M&A (Lymphotech). Management tempered near-term cadence expectations due to the new Medicare prior authorization process and flagged incremental expense and lower-margin grant revenue from the recent acquisition. On balance, operational and financial progress, upgraded guidance, and a strong product and innovation roadmap outweigh the manageable short-term execution and margin composition risks.View all TCMD earnings summariesTCMD Stock 12 Month Forecast
Average Price Target
$39.50
▲(53.52% Upside)
Technical Analysis
Sanuwave Health
―
Viemed Healthcare
―
Outset Medical
―
TriSalus Life Sciences
―
Ceribell, Inc.
―
Ownership Overview
3.33% Insiders
19.42% Mutual Funds
4.47% Other Institutional Investors
50.10% Public Companies and
Individual Investors